NCT02119468View on ClinicalTrials.gov

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 18, 2016

Study Completion Date

December 1, 2022

Conditions
Refractory Plasma Cell MyelomaRecurrent Plasma Cell Myeloma
Interventions
DRUG

ixazomib citrate

Given orally

DRUG

dexamethasone

Given orally

DRUG

pomalidomide

Given orally

Trial Locations (5)

30322

Emory University/Winship Cancer Institute, Atlanta

37203

Sarah Cannon Research Institute (SCRI), Nashville

55905

Mayo Clinic, Rochester

85259

Mayo Clinic, Scottsdale

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02119468 - Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter